• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center.儿童造血干细胞移植中的巨细胞病毒感染:单一中心原发性感染的危险因素及复发性和迟发性感染病例
Biol Blood Marrow Transplant. 2016 Jul;22(7):1275-1283. doi: 10.1016/j.bbmt.2016.04.004. Epub 2016 May 8.
2
Risk Factors Associated with Survival Following Ganciclovir Prophylaxis through Day +100 in Cytomegalovirus At-Risk Pediatric Allogeneic Stem Cell Transplantation Recipients: Development of Cytomegalovirus Viremia Associated with Significantly Decreased 1-Year Survival.巨细胞病毒感染风险患儿行异基因造血干细胞移植后第 100 天内更昔洛韦预防与生存相关的危险因素:与 1 年生存率显著降低相关的巨细胞病毒血症的发生。
Transplant Cell Ther. 2024 Jan;30(1):103.e1-103.e8. doi: 10.1016/j.jtct.2023.09.025. Epub 2023 Oct 6.
3
Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.胃肠道移植物抗宿主病患者巨细胞病毒血症和胃肠炎的发病率、危险因素及结局
Biol Blood Marrow Transplant. 2015 Jan;21(1):159-64. doi: 10.1016/j.bbmt.2014.10.004. Epub 2014 Oct 16.
4
Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients.儿童造血干细胞移植患者巨细胞病毒血症的危险因素及结局
J Microbiol Immunol Infect. 2017 Jun;50(3):307-313. doi: 10.1016/j.jmii.2015.07.011. Epub 2015 Aug 14.
5
Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.实时定量聚合酶链反应时代造血干细胞移植后巨细胞病毒抢先治疗:与实体器官移植受者的比较
Transpl Infect Dis. 2016 Jun;18(3):405-14. doi: 10.1111/tid.12542. Epub 2016 Jun 9.
6
Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources.异基因移植后巨细胞病毒感染:脐血与外周血及骨髓移植来源的比较
Biol Blood Marrow Transplant. 2007 Sep;13(9):1106-15. doi: 10.1016/j.bbmt.2007.06.006.
7
Cytomegalovirus Status and the Outcome of T Cell-Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.巨细胞病毒状态与T细胞充足的低强度异基因造血干细胞移植的结果
Biol Blood Marrow Transplant. 2016 Oct;22(10):1883-1887. doi: 10.1016/j.bbmt.2016.07.009. Epub 2016 Jul 25.
8
High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.大剂量阿昔洛韦和抢先使用更昔洛韦预防儿童外周血干细胞移植后巨细胞病毒病
Bone Marrow Transplant. 2004 May;33(9):931-5. doi: 10.1038/sj.bmt.1704463.
9
The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters.异基因造血细胞移植后巨细胞病毒感染的临床影响:为何寻求有效的预防措施仍很重要。
Blood Rev. 2017 May;31(3):173-183. doi: 10.1016/j.blre.2017.01.002. Epub 2017 Feb 2.
10
Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection.使用人类白细胞抗原(HLA)匹配的同胞供者进行异基因造血干细胞移植后晚期巨细胞病毒感染的危险因素:供体淋巴细胞输注和早期巨细胞病毒感染既往史。
Bone Marrow Transplant. 2004 Jul;34(1):21-7. doi: 10.1038/sj.bmt.1704528.

引用本文的文献

1
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.抗病毒细胞治疗增强造血干细胞移植前后 T 细胞重建(ACES):评估危险因素的儿科患者的两臂、开放标签、二期干预性试验。
Nat Commun. 2024 Apr 18;15(1):3258. doi: 10.1038/s41467-024-47057-2.
2
Cytomegalovirus Infection Post-hematopoietic Stem Cell Transplant: Incidence, Risk Factors, and Outcome in an Omani Cohort.造血干细胞移植后巨细胞病毒感染:阿曼队列中的发病率、危险因素及结局
Oman Med J. 2023 Nov 30;38(6):e567. doi: 10.5001/omj.2023.113. eCollection 2023 Nov.
3
Time-dependent analysis of the impact on early cytomegalovirus reactivation of HLA mismatch and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation from related donors in acquired aplastic anemia.获得性再生障碍性贫血患者接受亲缘供者异基因造血细胞移植后,HLA 错配和急性移植物抗宿主病对早期巨细胞病毒再激活影响的时间依赖性分析。
Ann Hematol. 2023 Sep;102(9):2589-2598. doi: 10.1007/s00277-023-05332-0. Epub 2023 Jul 13.
4
Cytomegalovirus in children undergoing haematopoietic stem cell transplantation: a diagnostic and therapeutic approach to antiviral resistance.接受造血干细胞移植儿童的巨细胞病毒感染:抗病毒耐药性的诊断与治疗方法
Front Pediatr. 2023 May 30;11:1180392. doi: 10.3389/fped.2023.1180392. eCollection 2023.
5
Features of cytomegalovirus infection and evaluation of cytomegalovirus-specific T cells therapy in children's patients following allogeneic hematopoietic stem cell transplantation: A retrospective single-center study.异基因造血干细胞移植后儿童患者巨细胞病毒感染的特点及巨细胞病毒特异性 T 细胞治疗的评价:一项回顾性单中心研究。
Front Cell Infect Microbiol. 2022 Oct 20;12:1027341. doi: 10.3389/fcimb.2022.1027341. eCollection 2022.
6
The Impact of High CMV Viral Load and Refractory CMV Infection on Pediatric HSCT Recipients with Underlying Non-Malignant Disorder.高巨细胞病毒(CMV)病毒载量和难治性CMV感染对患有潜在非恶性疾病的儿科造血干细胞移植受者的影响。
J Clin Med. 2022 Sep 1;11(17):5187. doi: 10.3390/jcm11175187.
7
Early pulmonary complications related to cancer treatment in children.儿童癌症治疗相关的早期肺部并发症。
Pediatr Radiol. 2022 Sep;52(10):2017-2028. doi: 10.1007/s00247-022-05403-w. Epub 2022 Jul 2.
8
Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients.抢先治疗巨细胞病毒的时机对儿科造血干细胞移植受者的总生存时间有影响。
Cytotherapy. 2022 Apr;24(4):428-436. doi: 10.1016/j.jcyt.2021.10.002. Epub 2022 Jan 15.
9
Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.危重症儿科造血细胞移植患者的综合预后评估:合并国际血液和骨髓移植研究中心(CIBMTR)与虚拟儿科系统(VPS)登记数据的结果
Biol Blood Marrow Transplant. 2020 Feb;26(2):333-342. doi: 10.1016/j.bbmt.2019.09.027. Epub 2019 Sep 26.
10
Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy.在意大利,接受异基因造血干细胞移植的巨细胞病毒血清阳性成年受者中,使用来特莫韦预防巨细胞病毒的成本效益分析。
Infect Drug Resist. 2019 May 8;12:1127-1138. doi: 10.2147/IDR.S196282. eCollection 2019.

本文引用的文献

1
Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation.巨细胞病毒可诱导适应性自然杀伤细胞和表达杀伤细胞免疫球蛋白样受体的T细胞反应,且这些反应与同种异体供体造血细胞移植后预防巨细胞病毒再激活相关。
Biol Blood Marrow Transplant. 2015 Sep;21(9):1653-62. doi: 10.1016/j.bbmt.2015.05.025. Epub 2015 Jun 6.
2
CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire.巨细胞病毒再激活驱动移植后T细胞重建,并导致潜在的TCRβ库出现缺陷。
Blood. 2015 Jun 18;125(25):3835-50. doi: 10.1182/blood-2015-03-631853. Epub 2015 Apr 7.
3
A single-center experience of cytomegalovirus infections in Asian pediatric patients undergoing allogeneic hematopoietic stem cell transplant for leukemia in Singapore.新加坡一家中心针对白血病患儿接受异基因造血干细胞移植时巨细胞病毒感染情况的经验总结
Transpl Infect Dis. 2014 Aug;16(4):556-60. doi: 10.1111/tid.12238. Epub 2014 May 23.
4
Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation.供者巨细胞病毒状态影响异基因造血干细胞移植的结局:欧洲血液和骨髓移植组的研究。
Clin Infect Dis. 2014 Aug 15;59(4):473-81. doi: 10.1093/cid/ciu364. Epub 2014 May 20.
5
Predictive factors of cytomegalovirus seropositivity among pregnant women in Paris, France.法国巴黎孕妇巨细胞病毒血清阳性的预测因素
PLoS One. 2014 Feb 24;9(2):e89857. doi: 10.1371/journal.pone.0089857. eCollection 2014.
6
Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT.代表 EBMT 的先天错误、传染病和儿科疾病工作组,对儿科异基因 HSCT 项目中的 CMV 管理进行调查。
Bone Marrow Transplant. 2014 Feb;49(2):276-9. doi: 10.1038/bmt.2013.164. Epub 2013 Oct 28.
7
Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review.造血干细胞移植后巨细胞病毒病:一篇小型综述。
Cancer Lett. 2014 Jan 1;342(1):1-8. doi: 10.1016/j.canlet.2013.09.004. Epub 2013 Sep 13.
8
A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group.异基因造血干细胞移植后早期巨细胞病毒再激活的风险评分可识别低、中、高风险组:仅在中风险组中,移植物抗宿主病会增加再激活风险。
Transpl Infect Dis. 2012 Apr;14(2):141-8. doi: 10.1111/j.1399-3062.2011.00706.x. Epub 2012 Jan 29.
9
Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.在监测和抢先治疗时代,移植前巨细胞病毒(CMV)血清学状态仍然是异基因造血干细胞移植后CMV重新激活的最重要决定因素。
Transpl Infect Dis. 2010 Aug 1;12(4):322-9. doi: 10.1111/j.1399-3062.2010.00504.x. Epub 2010 May 11.
10
Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation.脐血移植后巨细胞病毒(CMV)再激活的影响。
Biol Blood Marrow Transplant. 2010 Feb;16(2):215-22. doi: 10.1016/j.bbmt.2009.09.019. Epub 2009 Sep 26.

儿童造血干细胞移植中的巨细胞病毒感染:单一中心原发性感染的危险因素及复发性和迟发性感染病例

Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center.

作者信息

Rowe R Grant, Guo Dongjing, Lee Michelle, Margossian Steven, London Wendy B, Lehmann Leslie

机构信息

Stem Cell Transplantation Program, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute, Boston, Massachusetts; Boston Children's Hospital, Boston, Massachusetts.

Boston Children's Hospital, Boston, Massachusetts.

出版信息

Biol Blood Marrow Transplant. 2016 Jul;22(7):1275-1283. doi: 10.1016/j.bbmt.2016.04.004. Epub 2016 May 8.

DOI:10.1016/j.bbmt.2016.04.004
PMID:27090959
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5491305/
Abstract

Cytomegalovirus (CMV) infection is a significant source of morbidity and mortality in allogeneic stem cell transplantation (SCT). We identified a cohort of 91 pediatric SCT patients at risk (defined as either donor and/or recipient seropositivity) for CMV infection at our institution. We retrospectively categorized at-risk SCT recipients as those who (1) were at risk of CMV infection in the post-SCT period, (2) had documented CMV infection before SCT, (3) experienced recurrence of post-SCT CMV viremia, or (4) experienced late post-SCT CMV viremia; categories were not mutually exclusive. We analyzed the impact of SCT-related factors on incidence of CMV infection and outcome, and we described the outcome of each of these cohorts. In univariate analysis, recipient CMV seropositivity, use of umbilical cord blood graft, and acute graft-versus-host disease (GVHD) predicted post-SCT CMV viremia, and the effects of acute GVHD (odds ratio, 4.018; 95% confidence interval, 1.032 to 15.643) and CMV seropositivity (odds ratio, 16.525; 95% confidence interval, 2.041 to 133.803) were confirmed in multivariate analysis. Patients with recurrence of post-SCT CMV viremia had a 50% all-cause mortality rate, compared with 12% in all 91 patients. Patients with pre-SCT CMV infection had a high incidence of post-SCT CMV infection but could successfully undergo SCT with antiviral prophylaxis and pre-emptive CMV treatment. All patients with late CMV infection had prior GVHD. Theses findings identify risk factors for post-SCT CMV infection and provide novel descriptions of childhood SCT recipients with pre-SCT, recurrent, and late CMV infection, which may contribute to risk stratification strategies for CMV at-risk patients in pediatric allogeneic SCT.

摘要

巨细胞病毒(CMV)感染是异基因造血干细胞移植(SCT)中发病和死亡的重要原因。我们在本机构确定了一组91名有CMV感染风险(定义为供体和/或受体血清学阳性)的儿科SCT患者。我们回顾性地将有风险的SCT受者分类为:(1)在SCT后时期有CMV感染风险的患者;(2)在SCT前有记录的CMV感染患者;(3)经历SCT后CMV病毒血症复发的患者;或(4)经历SCT后晚期CMV病毒血症的患者;这些类别并非相互排斥。我们分析了SCT相关因素对CMV感染发生率和结局的影响,并描述了每个队列的结局。在单因素分析中,受体CMV血清学阳性、脐带血移植物的使用以及急性移植物抗宿主病(GVHD)可预测SCT后CMV病毒血症,多因素分析证实了急性GVHD(比值比,4.018;95%置信区间,1.032至15.643)和CMV血清学阳性(比值比,16.525;95%置信区间,2.041至133.803)的影响。SCT后CMV病毒血症复发的患者全因死亡率为50%,而所有91名患者的全因死亡率为12%。SCT前有CMV感染的患者SCT后CMV感染发生率较高,但通过抗病毒预防和抢先性CMV治疗可成功进行SCT。所有晚期CMV感染患者均有既往GVHD。这些发现确定了SCT后CMV感染的危险因素,并提供了对SCT前、复发和晚期CMV感染的儿童SCT受者的新描述,这可能有助于儿科异基因SCT中CMV风险患者的风险分层策略。